Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and ...

Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt se...

The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer...

Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, ci...

Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs.

A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the ...

Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda...

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a ro...

Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's dru...